1. Alberts DS, Young L, Mason N, Salmon SE (1985) In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achieved by intraperitoneal administration. Semin Oncol 3[Suppl 4]:38–42
2. Alberts DS, Surwit EA, Peng YM et al. (1988) Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administration. Cancer Res 48:5874–5877
3. Atallah D, Marsaud V, Radanyi C et al. (2004) Thermal enhancement of oxaliplatin-induced inhibition of cell proliferation and cell cycle progression in human carcinoma cell lines. Int J Hyperthermia 20:405–419
4. Baba H, Siddik ZH, Strebel FR et al. (1989) Increased therapeutic gain of combined cis-diamminedichlor oplatinum(II) and whole body hyperthermia therapy by optimal heat/drug scheduling. Cancer Res 49:7041–7044
5. Balthasar JP, Fung H-L (1996) Inverse targeting of peritoneal tumors: selective alteration of the disposition of methotrexate through the use of anti-methotrexate antibodies and antibody fragments. J Pharm Sci 85:1035–1043